Chronic Obstructive Pulmonary Disease Classification, Phenotypes and Risk Assessment

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2019 Oct 22

PMID 31632753

Citations 9

Authors

Prasad Manian

Affiliations

Soon will be listed here.

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. Various classification systems and phenotypes have been proposed. This review highlights the current classifications of COPD, describes the major phenotypes and provides a blue print for risk assessment of COPD. It is likely that more phenotypes and endotypes of COPD will be described paving the way to personalized medicine for patients with COPD.

Citing Articles

IgG Antibody Titers Against , , and in Venezuelan Patients with Asthma or COPD.

De Sanctis J, Moreno D, Larocca N, Garmendia J Trop Med Infect Dis. 2024; 9(11).

PMID: 39591259 PMC: 11598297. DOI: 10.3390/tropicalmed9110253.

The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis.

Li F, Zheng L, Xu X, Jin J, Li X, Zhou L BMC Pulm Med. 2024; 24(1):393.

PMID: 39143553 PMC: 11323643. DOI: 10.1186/s12890-024-03180-w.

Is Type and Grade of Emphysema Important for Bone Mineral Density and Aortic Calcifications?.

Vukovic D, Budimir Mrsic D, Ordulj I, Saric F, Tandara M, Jerkovic K J Clin Med. 2024; 13(13).

PMID: 38999515 PMC: 11242253. DOI: 10.3390/jcm13133947.

COPD deaths attributable to ozone in 2019 and future projections using the WHO AQG 2021 in urban China.

Yao M, Hu Y, Zhang A, Ji J, Zhao B Eco Environ Health. 2023; 1(4):251-258.

PMID: 38077259 PMC: 10702908. DOI: 10.1016/j.eehl.2022.11.002.

Polypharmacy Management in a Gender Perspective: At the Heart of the Problem: Analysis of Major Cardiac Diseases, SARS-CoV-2 Affection and Gender Distribution in a Cohort of Patients in Internal Medicine Ward.

Pietrantonio F, Ciamei A, Vinci A, Ciarambino T, Alessi E, Pascucci M Int J Environ Res Public Health. 2023; 20(9).

PMID: 37174229 PMC: 10178862. DOI: 10.3390/ijerph20095711.

References

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

DORNHORST A . Respiratory insufficiency. Lancet. 1955; 268(6876):1185-7. View

Burgel P, Paillasseur J, Peene B, Dusser D, Roche N, Coolen J . Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One. 2012; 7(12):e51048. PMC: 3517611. DOI: 10.1371/journal.pone.0051048. View

Sidhaye V, Nishida K, Martinez F . Precision medicine in COPD: where are we and where do we need to go?. Eur Respir Rev. 2018; 27(149). PMC: 6156790. DOI: 10.1183/16000617.0022-2018. View

Celli B, Cote C, Lareau S, Meek P . Predictors of Survival in COPD: more than just the FEV1. Respir Med. 2008; 102 Suppl 1:S27-35. DOI: 10.1016/S0954-6111(08)70005-2. View

Mirza S, Benzo R . Chronic Obstructive Pulmonary Disease Phenotypes: Implications for Care. Mayo Clin Proc. 2017; 92(7):1104-1112. PMC: 5587116. DOI: 10.1016/j.mayocp.2017.03.020. View

Agusti A, Hurd S, Jones P, Fabbri L, Martinez F, Vogelmeier C . FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J. 2013; 42(5):1391-401. DOI: 10.1183/09031936.00036513. View

Pascoe S, Locantore N, Dransfield M, Barnes N, Pavord I . Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3(6):435-42. DOI: 10.1016/S2213-2600(15)00106-X. View

10.

Agusti A, Celli B, Faner R . What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet. 2017; 390(10098):980-987. DOI: 10.1016/S0140-6736(17)32136-0. View

11.

Miravitlles M, Soler-Cataluna J, Calle M, Molina J, Almagro P, Quintano J . Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017; 53(6):324-335. DOI: 10.1016/j.arbres.2017.03.018. View

12.

Snider G . Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis. 1989; 140(3 Pt 2):S3-8. DOI: 10.1164/ajrccm/140.3_Pt_2.S3. View

13.

Lipson D, Barnhart F, Brealey N, Brooks J, Criner G, Day N . Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018; 378(18):1671-1680. DOI: 10.1056/NEJMoa1713901. View

14.

Cosio B, Soriano J, Lopez-Campos J, Calle-Rubio M, Soler-Cataluna J, de-Torres J . Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2015; 149(1):45-52. DOI: 10.1378/chest.15-1055. View

15.

Anzueto A . Impact of exacerbations on COPD. Eur Respir Rev. 2010; 19(116):113-8. PMC: 9682573. DOI: 10.1183/09059180.00002610. View

16.

Bujarski S, Parulekar A, Sharafkhaneh A, Hanania N . The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015; 15(3):509. DOI: 10.1007/s11882-014-0509-6. View

17.

Pinto L, Alghamdi M, Benedetti A, Zaihra T, Landry T, Bourbeau J . Derivation and validation of clinical phenotypes for COPD: a systematic review. Respir Res. 2015; 16:50. PMC: 4460884. DOI: 10.1186/s12931-015-0208-4. View

18.

Nishimura K, Izumi T, Tsukino M, Oga T . Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121(5):1434-40. DOI: 10.1378/chest.121.5.1434. View

19.

Rennard S, Calverley P, Goehring U, Bredenbroker D, Martinez F . Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Respir Res. 2011; 12:18. PMC: 3040135. DOI: 10.1186/1465-9921-12-18. View

20.

Kim V, Han M, Vance G, Make B, Newell J, Hokanson J . The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011; 140(3):626-633. PMC: 3168856. DOI: 10.1378/chest.10-2948. View